GT

Immediate_College918

2020 Subaru Lagacy GT

InvestigatorWooden33

Quickly, year make and model of your car 2019 Kia Stinger GT

Correct_Proposal_409

I hope so too. I’m sorry to hear about your diagnosis. Exciting developments with GT-02287. 90 day data should be out in the next few weeks. Meanwhile, Gain Therapeutics presented new data, which came out today, which shows how GT – 02287 helps recover mitochondrial function. This is a key piece of the puzzle. It’s looking like this treatment checks all of the boxes. Gain and/or whatever pharmaceutical partners with or acquires them will be gearing up for phase 2 likely in the United States. If you are in the US, perhaps you could be part of this study. Hang in there.

ByahhByahh

If 🌽 falls much further we're going to see an influx of GT3RS hit the market

MediumSinger8088

[Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 | Markets Insider](https://markets.businessinsider.com/news/stocks/gain-therapeutics-presents-preclinical-gt-02287-data-at-neuroscience-2025-1035581219)

Glam34

up 3k today GT CELH

ColdComplaint8

market finally waking up to good year($GT) I think we'll see $12 before mid dec

Correct_Proposal_409

Check out this article (linked below). The article explains how both Parkinson’s and Alzheimer’s begin with with misfolded proteins, a-synuclein and tau respectively, which causes a cascade of issues: p62 rises, autophagy stalls, lysosomes clog, and mitochondria start to fail. Once that cascade begins, neurons slowly lose function long before they die. GT-02287 seems to hit the first domino in that cascade. By stabilizing GCase before it reaches the lysosome, it restores proper enzyme trafficking, clears the backed-up protein waste (including α-synuclein and tau), lowers p62, reduces cellular stress, and should reboot autophagy and mitochondrial health. Btw, Gain has measured p62 before (see slide), and I wonder if it will be one of the biomarkers they’ll be measuring in the 1b. [https://newatlas.com/brain/same-mechanism-proteins-parkinsons-alzheimers/](https://newatlas.com/brain/same-mechanism-proteins-parkinsons-alzheimers/) And here’s the PubMed link: [https://pubmed.ncbi.nlm.nih.gov/41027737/?utm\_source=chatgpt.com](https://pubmed.ncbi.nlm.nih.gov/41027737/?utm_source=chatgpt.com) https://preview.redd.it/aek2tkwnoi1g1.jpeg?width=1241&format=pjpg&auto=webp&s=429bc654ee111a2dc475122e93a2652fab2c955a

Correct_Proposal_409

https://preview.redd.it/liydunxc5f1g1.jpeg?width=1284&format=pjpg&auto=webp&s=362b3c2f535995f3532c48efbe6ef92200e357a0 You’re right that dilution is common in biotech, and it in fact has been happening some via Gain’s ATM recently — but in Gain’s case it’s looking less and less likely that there will be a large, go-it-alone cash raise for P2. Gain has been in active discussions with a handful of mid- and large-cap pharmas for at least the last year, probably longer. Management has made it clear they do not want to run Phase 2 or Phase 3 alone, and these potential partners have already completed nearly all of their due diligence. At this point, the only missing piece is the biomarker data… and realistically, these companies either already have early access to it or will see it next week at Neuroscience behind closed doors. GT-02287 went into Phase 1b already mostly de-risked, with: • strong mechanistic clarity (ER → lysosome → mitochondrial rescue) • 53% GCase activity increase in healthy humans • full motor rescue in multiple animal models • dose-dependent reversal of α-syn and toxic lipids • safety and CNS penetration already proven The upcoming biomarker readout is essentially the final confirmation… no meaningful downside risk and enormous upside potential. Even (what I believe is) the base-case scenario (highly effective in GBA1 patients) is a multibillion-dollar market. Big pharma clearly does not necessarily wait for P2 anymore (see slide). If you’re Merck, AbbVie, Lilly, or Roche… why would you risk letting the first disease-modifying Parkinson’s drug in history slip to a competitor? Especially when: • 90%+ of PD patients have lysosomal / GCase pathway dysfunction • Early signals already include improved smell and balance — the rarest and strongest markers of disease modification • Gain’s market cap is \~$100M I this is exactly the point in development where large pharma steps in: after the biology is validated but before the price goes up 10×. Dilution is possible— but a partnership or acquisition is far more likely, and far more rational, given the competitive landscape and what’s at stake. Btw, they still have a significant amount of their ATM available, which they’ve been using strategically to add runway space.

Correct_Proposal_409

Forgot to address the UPDRS scores. Yes, their number is encouraging, but it was over 6 months I believe, not three months. So the scores are not better on a per month basis. With GT-02287, there were no changes at 30 days, but improvements at 90. This suggests no placebo effect. Not sure if there is data on that for Ambroxol. And it is unknown at what point the drug started improving motor symptoms. Was it at 30 days? at 60 days? It is thought that the improvements could be accelerating into 90 days and beyond, but this is unknown territory. Also, while anecdotal, patients reported a return of sense of smell, which can only point to a reversal of disease pathology.

Correct_Proposal_409

The increase of 35%, if I'm not mistaken, is an increase in protein concentration, not enzymatic activity, which I believe actually decreased. It is enzymatic activity that matters. GT-02287 increased enzymatic activity by 53% in healthy volunteers, which was surprising since it was thought that healthy volunteers would have near optimal levels and consequentially the drug wouldn't have much of an impact due to homeostasis. It is thought that GT-02287 will have an even bigger effect on actual Parkinson's patients, especially ones with GBA1 mutation.

yellowbreadletter

I think you should re-read the study data on Ambroxol a bit more carefully. They found a statistically significant increase of GCase levels in CSF of 35% which is quite a large increase. The decrease I believe you are referring to is the enzymatic activity of GCase in the CSF. Ambroxol is pH dependent. The pH of extracellular CSF is 7.4, due to its higher pH the GCase that is being tested in CSF does not allow the Ambroxol to detach from the GCase protein, therefore the protein can not function as an enzyme while bound to Ambroxol. Ambroxol is a weak base and binds to GCase at higher pH levels and detaches at lower pH levels, once reaching the lysosome where the pH is approximately 5.0 Ambroxol detaches from GCase allowing it to perform its enzymatic function. Study participants also showed an average of a 6.8 point reduction in MDS-UPDRS part III motor scale, which was a greater increase than was seen in the 1B trial for GT-02287. Certainly GT-02287 appears to be a better targeted treatment not requiring the patient to take 19 tablets per day, but if there is a generic that is "almost as good" then big pharma may be reluctant to make an acquisition here. I do look forward to reading the biomarker data on GT-02287 however.

Correct_Proposal_409

Yes, it has had underwhelming success to say the least. For whatever reason, it does not seam to increase Gcase activity consistently or impressively in the CNS (where it counts). In some trials, Gcase went down in the CNS. Preclinical work showed a little lysosomal clearing, but nothing like GT-02287, and no reduction of ER stress, improved mitochondrial function, reduced neuroinflammation like 2287 showed. Basically, not even considered competition.

Correct_Proposal_409

Thanks for your thoughts. That’s interesting about the neurotrophic response. I’ve heard the word thrown around before, but I didn’t know that this is what it meant. Sounds like this neurotrophic response is a part of neuroplasticity. I know that there are protocols to enhance autophagy, namely fasting, intermittent fasting, fast-mimicking diet. If/when the lysosome has recovered function (i.e., with GT-02287), autophagy should re-engage. Perhaps a fasting protocol would add synergy. May I ask if you are in a related field?

reddit_lemming

Bro, you gotta stop with the “bench” analogy. A top end GPU isn’t price inflated like a Rolls because of “exclusivity” and hand-stitched wool seats or whatever, it’s expensive because it’s using cutting edge tech to be fast as fuck on track, like a GT3 RS. You know what isn’t the fastest, but is still fast enough for most drivers to not notice the difference? A five year old previous gen GT3 RS. Rolls analogy is a straw man.

reddit_lemming

You’re right, they’re charging 911 GT3 RS prices. And you know what isn’t the FASTEST track car in the world, but is still pretty fucking fast? A previous gen 911 GT3 RS.

ImaginationRoutine96

You’re framing this like Gain is clueless about whether the drug gets into the brain, but that shows you haven’t actually looked at the data. They already measured CNS penetration in humans in the Phase 1 MAD cohort. It’s right there in the deck. Healthy volunteers showed clear CSF exposure of GT-02287 — 3.1 ng/mL on average, which matches the levels that worked in rodent models. The rodents actually had 2–8x higher drug levels in actual brain tissue than plasma, which is exactly what you want for a CNS drug. So no, they’re NOT “waiting to find out” if it crosses the BBB. They already know it does. The upcoming readout isn’t about basic penetration; it’s about confirming that long-term dosing in Parkinson’s patients produces consistent CNS levels and that those levels tie into: GCase activation, lysosomal + mitochondrial restoration, sphingolipid reduction and alpha-synuclein-related biomarkers On top of that, they’ve already shown functional improvement by Day 90 in the Phase 1b group. That alone sets them apart from pretty much every symptomatic PD treatment and most early “disease-modifying” attempts. And yes, other companies are working on Parkinson’s. That’s not the point. AskBio’s gene therapy is a totally different approach which is invasive, risky, and expensive. GT-02287 is an oral small molecule that restores GCase function across the entire disease cascade. If you actually compare mechanisms, they aren’t even in the same category. So the idea that Gain is behind or “doesn’t know” whether the drug hits the brain is just wrong. They already proved CNS exposure. What they’re about to share is the translation whether that CNS exposure, in actual PD patients, lines up with biomarkers and functional benefit. That’s the data big pharma waits for before writing a check.

Correct_Proposal_409

Absolutely correct. The other important point is that there doesn't need to be reversal of disease progression, or even stopping of disease progression. The first drug that SLOWS disease progression will be worth in the many billions. Yet GT-02287 is showing reversal to some degree.

Correct_Proposal_409

https://preview.redd.it/pwven8yh201g1.jpeg?width=1284&format=pjpg&auto=webp&s=56e0c4b9c277382b46e78a3cc95563f4cd1f5c17 Here are some recent early/ pre-clinical acquisitions just in the GBA1 drugs, all much lesser drugs with much smaller markets than GT – 02287. The upcoming data will prove the mechanism of action and effectively de-risk the drug. It would be foolish for large pharmas not to at least offer a partnership deal with upfront cash and milestones. It’ll get much more expensive for them to wait.

Correct_Proposal_409

While I expect that it will be fast-tracked since it has a good safety profile and since there is no current disease modifying treatment for Parkinson's, the company is not going to run the phase 2/3 study themselves. They've made it clear that they will partner with or be acquired by one of the handful of pharmas with whom they've been speaking. 90 day biomarker data along with UPDRS clinical assessment scores will be out in a few weeks. The CEO is confident that they will be consistent with the what they've already seen with the interim data and the patients who had already completed the 90 days. If and when this happens, talks with these "partners" will accelerate in earnest. I can't see them getting acquired for under $600 million. That would be a crime IMO. But I think it is more likely that it gets bid up. I doubt Merck wants one of their competition to own a drug that makes their treatments obsolete. The question is how much will they pay? Pfizer just did a deal for $10 billion for two weight loss drugs with a lower estimated peak yearly revenue (than a first and only disease modifying Parkinson's drug), and those two drugs might take longer to get to market than GT-02287.

microcapreturns

Patients had their ability to smell return. HUGE. Leveraging AI: The Biotech Cracking the Code on Rare Diseases https://youtu.be/CJcH-n6iKVU?si=BWkW1cEYdv71FN9X CEO Gene Mack: This is a buy at $10, $15 or $20. Multibillion revenue opportunity per year. Alzheimers,  Gaucher and other neurological diseases also possible. Patients saw functional improvement in motor functions, tremors, balance and regained smell after only 90 days on GT-02287. Patients and clinicians requested extension of trial so they wouldnt lose the improvements they have seen.

HartbrakeFL21

Hell yeah. I've got some old Mustang GT parts laying around that I'm re-gifting for Xmas.

Glam34

Im betting on GT. Reducing debt but got hit hard by rubber tariffs. Even if they dont get struck down, i think theyll be on the short list of "natural resources that cant be produced in u.s." that will get rid of them.

Correct_Proposal_409

Sounds like you have synesthesia. GT-02287 might help you with that.

TickTockTaudit

Absolute peak 90s is Einstein on the Beach by Counting Crows. Song fucking rips. Had a Fox body Mustang GT convertible, smoking Marlboro Lights, drinking Wawa iced tea. I’d go back in time if I could.

ColdComplaint8

any $GT tire bros out there?

Correct_Proposal_409

See my other response to you below, but this illustrates why dilution is zero concern for me. Pfizer just won a bidding war to acquire Metsera for $10 billion for their two GLP-1 (weight loss) drugs that may not get to market before Gain’s GT-02287. Those two drugs are estimated to have peak sales of $5 billion per year, whereas the first disease modifying drug for Parkinson’s would be somewhere in the $5 billion to $30 billion range. Due to the nature of Parkinson’s disease and they’re being no disease modifying treatment, GT-02287 could be expedited through the development process and available within 2 to 3 years, maybe less. https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-sweetens-offer-metsera-bidding-war-against-novo-bloomberg-news-reports-2025-11-08/

Correct_Proposal_409

This drug helps Parkinson’s patients, but it has been shown pre-clinically that the same enzyme, GCase — which the drug chaperones to the lysosome and beyond so it can do its job — is responsible for clearing out toxic substrates that build up inside neurons. In Alzheimer’s, those toxic substrates take the form of misfolded tau and amyloid proteins. By restoring GCase function, GT-02287 could help the brain clear these aggregates at their root cause, improving lysosomal and mitochondrial health — the same cellular systems that collapse in both Parkinson’s and Alzheimer’s.

Correct_Proposal_409

Very good point. GT-02287 clears the lysosome of tau (one of prime suspects for Alzheimer’s) just like it clears a-synuclein for Parkinson’s.

Correct_Proposal_409

Too early for what, buyout? Sanofi just acquired Vigil for $470 million for a phase 1 Alzheimer’s drug. Merck and Abbvie both bought pre-clinical GBA assets for over $600 million each ($100 million up front plus milestones). Merck also bought Calporta for their lysosomal treatment for $576 million. None showed disease modification like GT-02287, which it has shown both pre-clinically, and now in actual Parkinson’s patients.

ColdComplaint8

going full regarded and doubling my $GT dec calls when market opens, have 150 now.

Correct_Proposal_409

At Neuroscience, they will be presenting new data about how GT – 02287 improves mitochondrial function. It was designed to enable Gcase to clear out the lysosome, but they’ve since learned that Gcase also plays an important role in the mitochondria. In Parkinson’s disease, there are multiple points of failure within neurons — lysosomal dysfunction, mitochondrial breakdown, and α-synuclein accumulation — all feeding into neurodegeneration. You can’t just fix one area and expect recovery. GT – 02287 seems to repair these interconnected systems by restoring Gcase. It is very unlikely that they will present any new data regarding the phase 1B, since they did not have that data a couple months back at the deadline for submitting what they will present. But it doesn’t necessarily mean that they can’t release some new data prior to neuroscience, and it definitely doesn’t mean that they won’t be talking to big pharma at Neuroscience with whom they have NDA’s about the latest bio markers and clinical improvements in the 1b patients.

Glock7enteen

I’m rich (buy a GT3 RS in cash rich), tall, somewhat good looking, full head of hair, still young but I’m depressed asf and would give absolutely everything up just to get my ex back lmao

ImaginationRoutine96

That’s a fair take, but it misses what Gain Therapeutics is actually signaling with their capital structure and trial design. They aren’t trying to fund a Phase 2 or 3 internally, that’s intentional. The company strategically left enough cash runway to complete their biomarker data readout and advance the asset to a Phase 2 ready stage, because that’s the inflection point where strategic partnerships or outright acquisition deals usually happen in biotech. Management has been clear that their goal is not to dilute shareholders to fund a multi year, multimillion dollar Phase 2 or 3. Instead, they’re positioning GT-02287 to be de-risked, showing both safety and early efficacy signals, right before larger pharma steps in. This is the same approach used in many CNS and rare disease deals where early proof of mechanism drives billion dollar valuations, like we’ve seen with Denali, Cerevel, and Neurocrine. As for competition, yes, others are in the race, but GANX has shown actual functional improvement, including patients regaining sense of smell, reduced tremors, and improved balance. Those outcomes are something no other Parkinson’s therapy has achieved so far. They point to disease modification, not just symptom relief. If the upcoming biomarker data confirms blood brain barrier penetration and reduction of alpha synuclein, they’ll have something the rest of the field doesn’t, real proof of disease modifying effect in humans. So the low insider buying narrative misses the bigger picture. Management isn’t betting on long term internal development, they’re betting on a near term strategic transaction once the data validates the science.

ImaginationRoutine96

Regaining the sense of smell is a game changer. Roughly 90% of Parkinson’s patients lose smell permanently, and no drug in history has ever restored it, until now. In Gain Therapeutics’ Phase 1b trial, patients regained smell, improved balance, and saw reduced tremors after just 90 days of GT-02287 treatment. That’s not placebo. That’s disease modification in action, and it’s now backed by hard data from the company’s newly released scientific poster, which shows consistent functional improvement and favorable safety. These are the kinds of results that attract serious pharma attention.

Correct_Proposal_409

BTW, it wasn't just a fluke. GT-02287 was designed to do exactly this, and they did a ton of pre-clinical work which also predicted that it should work in humans with PD. Every step along the way has been further confirmation that it works. The only surprises along the way were to the upside. For example, they were very confident it would work in the GBA1 subset, but weren't confident about idiopathic populations. Now they are seeing it helps both.

Correct_Proposal_409

Your information is outdated. Sanofi just acquired Vigil for $470 million for a phase 1 Alzheimer’s drug. Merck and Abbvie both bought pre-clinical GBA assets for over $600 million each ($100 million up front plus milestones). Merck also bought Calporta for their lysosomal treatment for $576 million. None showed disease modification like GT-02287, which it has shown both pre-clinically, and now in actual Parkinson’s patients. Not sure where you get “not that promising”. What can be more promising than showing for the first time in history a reversal of disease pathology in only 90 days?? The phase 1a was with healthy volunteers, and they are finished the 90 day period in the phase 1b with Parkinson’s patients. There is no other explanation for a return of the sense of smell other than disease modification. There will be a licensing deal, a partnership, or buyout in the next five months. A buyout will be north of $600 million, and likely $1 billion or above. Mark this post.

TickTockTaudit

Why GT?

East-Rub-231

Goodyear (GT)

Apenerd

GT-R’s aren’t worth it anymore, try finding a clean 991 Turbo S or 997.2 Turbo S.

Metacog_Drivel

So hard to find a used GT-R that hasn't been in an accident or salvage title or stolen or has been modded to hell. Maybe it's not meant to be.

ColdComplaint8

Any $GT tire bros up yet? Hope we can push past $9 today!

Fun-Conflict2110

GT tires baby

Sykre-

GEV and BKR are both good candidates, they provide both STD GT and aeroderative design like LM2500 or LM6000

ColdComplaint8

GT is up almost 10% today, lets go! It's going to be a GOOD YEAR!

ColdComplaint8

I have been watching Goodyear GT lately and it feels like something is building up. The stock has been moving up quietly and volume is picking up. The December options chain looks too cheap for how volatile this stock can be. I grabbed some 10 dollar calls expiring December 19 for 10 cents each. I know it is a total lotto but it is only 45 days out and if this thing moves it could move fast. The stock is at 7.40 right now and I just have a feeling a squeeze might be forming. There is not much news but short interest still looks solid and the chart looks like it wants to push higher. Could be nothing or it could surprise everyone. Anyone else watching GT or am I just setting money on fire for the smell of rubber

CatSuyac

I’ll save a seat for you in my GT63 when this bangs <3

patright333

Intrigued by GT after the pullback this year.

AcademicStandard3701

GT3’s are so sick absolute dream car. When ever I reach the top.

nomorelosses1

A cayenne? Gross. GT3 or bust

PineappleColada25

I'm $10k in on GT right now

nismoghini

Bro could have bought a 911 GT3rs and made his money back 🤣🤣

volckerwasright

And your reward has been lagging the companies who've acted irresponsibly during the rally, and you will get to bail them out when the ETF starts selling GT to raise cash.

volckerwasright

Geo, you're being comically obtuse. The entire sector is massively inflated since the June rescheduling hype began, and your beloved GT is the worst performer out of all of them. You can choose to baghold through the next drawdown, I'm not interested in that.

JordFxPCMR

GT3RS is calling your name

Fast-Culture-680

I have 10 shares of Nokia. GT3 RS, Baby

armankordi

most of my cars are $1200/one time purchase lol my most recent one was $800 (03 vibe GT)

UsualPay5570

Been watching GT… stock looks like it’s been pushed down hard, but the spring feels loaded. If volume shows up, could this thing finally snap back and send?

UsualPay5570

I saw GT has been going down for a while. Do you think something could happen that makes it go up again? Curious what you think

UsualPay5570

Maybe GT about to go full short squeeze mode. Hedgies loaded up thinking tires are dead money — but this thing is coiled tighter than my margin account on a Friday. One spark and it’s 🚀🚀🚀. Not financial advice, just a degenerate watching rubber burn

jer_nyc84


sssanguine

Should have fired their founder years ago. He’s an engineer LARPing as an innovator. Originally wanted to make a sports car to generate hype (Tesla, Fisker, Lightning GT), but this was years after the novelty of that wore off. Then pivoted to pickups forgetting that most pickup owners are semi culty already. Should have launched with a dope outdoorsy CUV, then made a SUV, then maybe a truck. Instead this guy lead them down the path of losing $30k+ per car with no end in sight

HealthyAirport

You ain’t getting that GT is all I’m saying lmao

FuckElonMuskkk

Why do people think China is hurting and need a deal too? They are busy buying their children going to Harvard and UCLA GT-Rs and throwing giant, elaborate drone shows. They literally do not give a single fuck. Their exports have gone up. Donnie would have to pick Xis taint and hand over Taiwan for them to let us off the hook.

AutoModerator

Hello 2023_GT, Your comment has been removed because you have an unverified email. Please follow [This Tutorial](https://www.wikihow.tech/Verify-Email-on-Reddit) to learn how to verify your email. *I am a bot, and this action was performed automatically. Please [contact the moderators of this subreddit](/message/compose/?to=/r/Shortsqueeze) if you have any questions or concerns.*

AutoModerator

Hello 2023_GT, Your submission has been removed because you have an unverified email. Please follow [This Tutorial](https://www.wikihow.tech/Verify-Email-on-Reddit) to learn how to verify your email. *I am a bot, and this action was performed automatically. Please [contact the moderators of this subreddit](/message/compose/?to=/r/Shortsqueeze) if you have any questions or concerns.*

patright333

Took long positions on GT and TMUS as well as BYND.

gopoohgo

Am old.   My retirement present to myself is an Aston DB12 or Bentley Continental GT

ImmySnommis

The same six core stocks I've always bought. AXP, COST, MSFT, DE, AAPL and ORI. Sure I dabble in other stuff (thank you ASTS!) and I'll take small fliers on interesting stories (right now GT, KDP, QXO) but I buy my core six on moderate dips and carry on.

InvestigatorWooden33

Driving a jeep because my KIA STINGER GT GUYS ITS A STINGER, is in the shop. Have a lot of grown ass men waving at me, it might be gayer than being a ber

getapuss

GT

Jerikolol

GT = Xx\_MLG\_Snip3R\_xX add me

MontyNinjaPython

The gains of the last two months have nothing to do with rescheduling. Companies made losses over years and have massively expanded or diversified and are now finally becoming profitable. GT, SNDL, OGI, etc etc. Trulieve eg. now has a 62 percent margin. Rescheduling will help, sure. But it will also speed up the brutal consolidation. 

JusGimmieMyMuuuhney

\*Ford GT. We are not the same.

ComplexProof9444

Btw I screenshotted this post so I can make sure to tag you when I cop a GT3RS based on purely CCCX gains

Thick-Material-5675

Only Asians will buy a model Y..You could get a VW Golf R, Honda Civic Type R or Corolla GT for same price and smoke them in a 1/4 mile while actually enjoying what you drive

hatmatter

Chapo did a great episode on the Dinar six years ago https://youtu.be/ubyQ1lSDglg?si=GT-kb5dVEBpRUfsh

Glam34

Get in losers. GT bouncing back to 11.

PineappleColada25

Why is GT down almost 4% today?

gami2billy

ya trade in the 2 for the GT

Pristine_Wind_5188

How do I turn $2500 into a GT500?

cultoftheclave

Was that what was on the sticker? I just leased an EV9 using this approach and the car's sticker was something like 76k, but after a bunch of incentives for leasing it was down to 64k, and was able to negotiate a sizeable further discount from there. I'm certain that they would've done something similar for the EV6 so unless you were getting the GT spec your number should've been lower by a lot.

chucho707

tendies and a poppi soda + a 2 hour session on the Nurburgring in the Ferrari 296 GT3 on iRacing

montybeta

Dude if it goes to 550, I will let you...while I'm sitting in my brand new Bentley GT.

JusGimmieMyMuuuhney

Feel guilty too, but a GT3 RS won’t fund itself.

PurposeNo6478

https://preview.redd.it/cry461on0qqf1.jpeg?width=1080&format=pjpg&auto=webp&s=864bde761469c585d7d11720b433645a2dc446f1 50,000 💪 come on I need my GT3 RS

gonewildpapi

Eating dinner with some family and wow some people sure suck off Elon Musk. Like man, you haven’t experienced a G63 or GT3RS to know that much better exists.

Traderparkboy1

Very risky and most likely not worth the reward, but I like these for penny stocks BBAI, DNUT, BB, LIDR. Just about penny stock is GT, ACHR, KOSS,NIO, Penny stocks are scary and a great way to lose half your money at an accelerated pace.

CultofCedar

I mean imma do it cause I can but pos Tesla is 6 years and I rarely use the brakes, never even changed them. Gotta stick with the EVs purely because I’ve got solar (sponsored by JPow) that over produces and I get paid 10¢ per kw to fuel my car. GT3 isn’t off the table for the future. Would be sick af picking my kids up in one in the future lmao.

Muted_Thought8382

GT3 or go home

wolf_of_rapestreet

GT-i386 turbo

Traderparkboy1

I stick to things I can see day to day and can confirm they actually make sales, are a part of daily life. Right now I’m gambling on DNUT, it’s beat down, but I know that tomorrow the stores will be open , they will be selling coffee and donuts . I also hold GT Goodyear tire 🛞 it’s technically not a penny stock , but it’s only 8.50 and in my opinion well worth the as, tires are pretty important in my opinion and I don’t see an end to demand anytime in the near future.

MyCactusTeacher

GT is an interesting one

Mindless-Wrangler651

if you're in the market to buy storage, do you want the '87 Buick , or the '25 Mustang GT?

infinite_cura

Do you feel cool by just turning off a heater? of course not. but it helps. you know S3 doesn't really do much but allow more research and relieve unfair taxation. but just does cutting some tax make them prosperous instantly? it helps but does it turn things around completely? i have suffered for many yrs and moved onto tech sectors. i am not a short nor manipulator. just think about it for the wknd. you are investing in companies that have struggled to pay taxes for many years (except GT). would removing some taxes drastically help them to in S3 when S3 doesn't really change things? if you are confident, don't be offened. you are only offended because you know you are fucking gambling and scared AF.

drew-gen-x

I picked up 3 small cap trucking & transportation stocks today. $HTLD that someone else here mentioned a few weeks ago, $GT and $WNC. Trucking & Transportation has been in a recession for over 2 years. Interest rate cuts should help the struggling non silicon valley economy more than the $QQQ.

FewMotor2009

Probably buy a Porsche 911 GT3 RS 😎

Candy_Shop3

Bro turned Ford stock into a Mustang GT 🚀

volckerwasright

Even best in class like GT will lose 30% on a negative S3 headline. The ETF ties everyones’ fates together. Don’t get me wrong, I agree with your point in general, but there are a unique set of circumstances at play here as a result of these stocks being OTC and federal reform being already priced in to some degree

Traderparkboy1

NOK, BBAI, LIDR, OPEN,ACHR,GT,DNUT. Some are above 5 bucks but under 10.